<DOC>
	<DOCNO>NCT01068613</DOCNO>
	<brief_summary>This study assess bronchodilator effect multiple dos QAX028 two different dose level compare tiotropium placebo COPD population .</brief_summary>
	<brief_title>Safety Efficacy Multiple Doses QAX028 Chronic Obstructive Pulmonary Disease ( COPD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Diagnosis COPD accord GOLD guideline Postbronchodilator 30 % â‰¤FEV1 &lt; 80 % predict normal ostbronchodilator FEV1/FVC &lt; 0.7 Smoking history least 10 pack year Requiring oxygen therapy daily basis Exacerbation airway disease 6 week prior screen screen dose Lung reduction surgery Respiratory tract infection 6 week prior screen Significant cardiac history History asthma onset symptom prior age 40 year Active use certain COPD medication , beta blocker Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>Long act muscarinic antagonist</keyword>
</DOC>